Immunovant, Inc. IMVT Income Statement
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| $456.66M+26.5% | $408.02M+22.4% | $403.62M+40.6% | $386.64M+62.6% | $360.92M+69.5% | ||
| $76.24M-1.3% | $79.15M+10.1% | $83.49M+27.8% | $84.45M+39.2% | $77.24M+34.8% | ||
| $532.9M+21.6% | $487.17M+20.2% | $487.11M+38.2% | $471.09M+57.8% | $438.15M+55.0% | ||
| $25.33M+2.4% | $24.16M-7.9% | $23.42M-23.4% | $23.89M-14.9% | $24.73M-0.9% | ||
| $2.18M+364% | $2.45M+177% | $1.25M+250% | $1.63M+213% | $470K+147% | ||
| -$505.39M-22.4% | -$460.56M-20.5% | -$462.44M-43.3% | -$445.58M-63.9% | -$412.95M-59.6% | ||
| —— | $3.64M+576% | $2.24M+704% | $1.73M+164% | $890K+57.0% | ||
| -$505.61M-22.2% | -$464.2M-21.3% | -$464.69M-43.9% | -$447.3M-64.1% | -$413.84M-59.6% | ||
| -$2.78-1.8% | -$2.68-2.3% | -$2.83-27.5% | -$2.84-47.2% | -$2.73-43.7% | ||
| -$479.65M-23.7% | -$435.97M-22.6% | -$438.61M-50.3% | -$421.29M-73.0% | -$387.84M-66.0% | ||
| -$480.06M-23.7% | -$436.4M-22.6% | -$439.03M-50.3% | -$421.69M-72.9% | -$388.22M-66.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immunovant, Inc. profitable?
- Immunovant, Inc. is not currently profitable: it reported a net loss of $505.6M over the trailing twelve months.
- What is Immunovant, Inc.'s earnings per share?
- Immunovant, Inc.'s diluted EPS over the trailing twelve months is $-2.78.
- Where does Immunovant, Inc.'s income statement data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.